Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;16(5):440-447.
doi: 10.1007/s11899-021-00654-0. Epub 2021 Oct 15.

Challenges in Chronic Myeloid Leukemia Management in South America

Katia B Pagnano  1 , Ana Ines Varela  2 , Carolina Pavlovsky  3 , Israel Bendit  4 , Vaneuza A M Funke  5 , Virginia Abello Polo  6
Affiliations
Review

Challenges in Chronic Myeloid Leukemia Management in South America

Katia B Pagnano et al. Curr Hematol Malig Rep. 2021 Oct.

Abstract

Purpose of review: Chronic myeloid leukemia (CML) management in developing countries has improved in the last years, but the availability of therapeutic resources, monitoring, reimbursement, and financial issues may be a challenge and interfere with the best practices and results of CML treatment. This review points out the main challenges in CML management in South America.

Recent findings: In this review, we describe the access to tyrosine kinase inhibitors and monitoring in different countries of South America. We also address the ongoing discontinuation trials, the progress, and limitations of hematopoietic stem cell transplantation in the last years. There are still many challenges for achieving the best outcomes for CML patients in South America. The continuous efforts to provide continuous education, access to tyrosine kinase inhibitors, and monitoring, providing reference centers for CML management and hematopoietic stem cell transplantation may improve patients' outcomes.

Keywords: Chronic myeloid leukemia; Hematopoietic stem cell transplantation; Management; Monitoring; Treatment-free remission; Tyrosine kinase inhibitors.

PubMed Disclaimer

References

    1. Cortes J, De Souza C, Ayala-Sanchez M, Bendit I, Best-Aguilera C, Enrico A, et al. Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer. 2010;116(21):4991–5000. - DOI
    1. Pavlovsky C, Mela Osorio MJ. Chronic myeloid leukemia: what is the best strategy to start and monitor treatment outside academic centers? Curr Oncol Rep. 2018;20(1):4. - DOI
    1. Abello-Polo VS-M, Claudia Peña, Angela et al. ACHO (Asociación Colombiana de Hematología y Oncología), RENEHOC researchers. Impact of Insurance Differences in Outcomes in Colombian Patients with Chronic Myeloid Leukemia (CML). Clinical Lymphoma, Myeloma and Leukemia. 2020:S240
    1. Méndez Y, Giraldo-Castaño Mn, Rocha MF. Estudio sobre la identificación de necesidades emocionales, sociales y de acceso a los servicios de salud, de los pacientes diagnosticados con leucemia mieloide crónica en Colombia https://www.funleucemialinfoma.org/wp-content/uploads/2019/07/Paper-Estu... : Fundación Colombiana de Leucemia y Linfoma; 2018. Accessed 11 Apr 2021.
    1. Ylescas-Soria J, de la Torre-Lujan AH, Herrera LA, Miranda D, Grimaldo F, Rivas S, et al. Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute - Mexico, from 2000 to 2016. Cancer Med. 2019;8(6):2942–9. - DOI

MeSH terms

Substances

LinkOut - more resources